Loading...
Conventional imaging for prostate cancer — computed tomography (CT) scans of the abdomen and pelvis and bone scans — has long been used to determine the presence or absence of metastatic disease in men with clinically localized disease with high-risk features. The recent FDA approvals of both gallium- and fluoride-based prostate-specific membrane antigen (PSMA) PET/CT in men with biochemical recurrence was based on trials demonstrating higher detection rates than obtained with conventional imaging.
In a prospective, single-arm, phase 3 study at two institutions, patients with intermediate- to high-risk disease being evaluated for radical prostatectomy each underwent a 68Ga-PSMA-11 PET study using either PET/CT or PET/MRI. Images were interpr…